An Open-Label Phase 1 Study to Evaluate the Safety of ATA188 in Subjects with Progressive and Relapsing-Remitting Multiple Sclerosis
The purpose of the study is to determine the safety and tolerability of ATA188 in subjects with progressive forms of multiple sclerosis. Up to 42 male or female subjects with progressive forms of MS and 42 subjects with Relapsing-Remitting MS will be enrolled. The subjects will be randomized to receive study drug or placebo and will receive 2 treatment cycles followed by 11 monthly follow-up visits.
- Study Identifier: 830135
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required